ZS Pharma To Present Data From Phase 3 Trial Of ZS-9 In Late-Breaking Oral Presentation At National Kidney Foundation’s 2014 Spring Clinical Meetings
4/22/2014 6:51:18 AM
ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that data from a pivotal Phase 3 trial of ZS-9, an investigational treatment for hyperkalemia, will be presented as a late-breaking clinical trial oral presentation at the National Kidney Foundation’s 2014 Spring Clinical Meetings in Las Vegas.
Help employers find you! Check out all the jobs and post your resume.
comments powered by